MetaCap

TRex Bio (TRXB) vs X4 Pharmaceuticals (XFOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

X4 Pharmaceuticals is the larger company by market cap ($306.3 million vs $297.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TRXB-26.32%XFOR+3.09%
+18%-9%-35%
Oct 9, 20261 yearNov 20, 2026
TRXB-26.32%XFOR+3.09%
+17%-6%-28%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TRXB versus XFOR key metrics
MetricTRXBXFOR
Share price$10.32$3.00
Market cap$296.95M$306.34M
1-day change+6.12%+1.35%
YTD return—-25.00%
1-year return—-20.00%
5-year return—-97.79%
P/E ratio (TTM)—5.45
EPS (TTM)$-2.74$0.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.50M
Revenue growth (YoY)—+150.00%
Net income (latest FY)—$-79.20M
Gross margin—11.43%
Operating margin—-1336.66%
Net margin—-1218.45%
52-week high$16.56$4.83
52-week low$9.06$2.43
Distance from 52-week high-37.71%-37.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+183.57%+286.67%
Average volume156.80K877.70K
Shares outstanding28.79M102.11M
Employees6045
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About TRex Bio

TRXB stock →

TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About X4 Pharmaceuticals

XFOR stock →

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees

TRXB vs XFOR FAQ

Which is bigger, TRex Bio or X4 Pharmaceuticals?

X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $306.34M compared with $296.95M for TRex Bio (TRXB).

Are TRex Bio and X4 Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons